Dow Plummets 200
Stocks slipped Tuesday as investors awaited the Federal Reserve’s policy decision and watched for signs of progress in global trade deals.The Dow Jones Industrials fell 210.62 points to 41,008.21.The much broader index skidded 36.12 points, to 5,614.26.The NASDAQ Composite faded 151.15 points to 17,693.09Tech giants Nvidia and Meta Platforms lost more than 1%. Shares of Tesla shed more than 2% after the company’s new car sales in Britain and Germany fell to their lowest in more than two years in April, even though demand for electric vehicles grew. Goldman Sachs shares also declined to pull the Dow lower.Trump is scheduled for meetings with Prime Minister Mark Carney on Tuesday, marking the start of negotiations between the two leaders since Carney assumed office in March. The meeting comes after Treasury Secretary Scott Bessent said on Monday that “we’re very close to some deals,” echoing comments from Trump on Sunday that agreements could come as early as this week. A Bloomberg report citing people familiar also said that India has proposed zero tariffs on certain goods. Prices for the 10-year Treasury hesitated, raising yields to 4.36% from Monday’s 4.34%. Treasury prices and yields move in opposite directionsOil prices jumped $2.32 to $59.45 U.S. a barrel. Prices for gold skyrocketed $83.60 to $3,405.90 U.S.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


